⏱ 1 Day66D5 score
SELLMRNA
Entry$194.50
Live$202.63
Today▼ -15.61%
Since pick▼ -4.18%
+33% vs analyst target · new source · 2 agree · 1 dissent
Why SELL: Our read: the melanoma-vaccine 'sell the news' selloff (-18% Thursday, ~$24B lost) is still running, -4% more premarket.
⚠ Analysts call the 42% risk cut 'solid' and 'exceptional'; full data hits ESMO Saturday and Brookline now targets $250.